RD NEPHROLOGIE SAS

Their core work

RD Nephrologie SAS is a private French R&D company based in Montpellier focused on kidney disease research and clinical development. They specialize in the biological connections between renal dysfunction and cardiovascular disease, including the mechanisms driving cardiorenal syndrome and chronic kidney disease (CKD) progression. In EU research networks, they participate as an industry partner contributing clinical and translational expertise to doctoral training consortia. Their recent work extends into systems-level analysis — using multi-omics methods to map the gut-kidney axis and understand how gut microbiome changes interact with kidney failure.

What they specialise in

How they've shifted over time

In their first documented EU project (CaReSyAn, 2018–2021), RD Nephrologie focused on the cardiorenal syndrome from a clinical and integrative analysis perspective, with no specific omics or microbiome keywords recorded. By 2020, their second project (STRATEGY-CKD) reflects a clear methodological evolution: the focus moved toward systems-level biology, multi-omics data integration, and the gut-kidney axis — areas that require computational and biochemical depth beyond traditional nephrology. This trajectory suggests the company is building capacity at the intersection of clinical nephrology and translational systems biology.

RD Nephrologie is moving from clinical syndrome characterization toward mechanistic, data-driven research using omics — positioning itself at the translational boundary between academic systems biology and clinical nephrology applications.

How they like to work

RD Nephrologie has participated exclusively as a consortium partner, never as project coordinator, across both MSCA Innovative Training Networks. Their participation in two large doctoral training networks — each typically comprising 10–15 partners — suggests they function as specialist industry nodes that anchor academic networks with clinical and commercial relevance. With 20 unique partners across 9 countries from just 2 projects, they appear to join broad, internationally diverse consortia rather than repeat collaborations with the same partners.

RD Nephrologie has accumulated 20 unique consortium partners across 9 countries despite only two projects, indicating participation in large, multi-national MSCA training networks. Their network is predominantly European, consistent with MSCA-ITN programme requirements.

What sets them apart

RD Nephrologie is an unusual participant in EU research training networks: a private nephrology SME embedded within academic doctoral consortia, where most industry partners are large pharma or device companies. This gives them a position as a clinical translation bridge — they can ground academic omics research in real-world kidney disease management and patient-facing applications. For a consortium builder, they represent the rare combination of specialist clinical domain knowledge (nephrology, cardiorenal disease) and openness to experimental, systems-level research directions.

Highlights from their portfolio

• STRATEGY-CKD
  The only funded project in the dataset (EUR 274,802), it is also the more methodologically advanced — applying system omics to the gut-kidney axis in CKD, a rapidly growing research frontier.
• CaReSyAn
  Their first EU project, focused on cardiorenal syndrome — a clinically significant but underserved intersection of heart and kidney failure — establishing their core disease focus.